Fig 1: Computed tomography of the thorax showing a mass in the lower lobe of the left lung.
For hamartomas, the age of presentation is 50 to 60 years, with a male/female ratio of 3-5/1. In our case, the patient was a 38-year-old female. The size of hamartomas may range from 1 cm to larger than 10 cm, but they are usually smaller than 4 cm.
Intraparenchymal hamartomas are usually asymptomatic. However, they may cause complaints like chest pain, dyspnea, cough, and hemoptysis. When the tumor becomes large enough, it may obstruct a bronchus causing atelectasis and recurrent or persistent pulmonary infection. It may sometimes be mistaken for chronic obstructive pulmonary disease, pneumonia, and tuberculosis. Our patient had complaints of cough and dyspnea for more than four years and received medication with a diagnosis of chronic bronchial asthma.
Diagnostic imaging methods include chest roentgenogram, computed tomography, magnetic resonance imaging, and bronchoscopy. In general, hamartomas are discovered incidentally on routine chest roentgenograms as an asymptomatic coin lesion. On chest roentgenograms, intraparenchymal hamartoma appears as a sharply outlined, round or oval mass, with lobulation, calcification, peripheral location, and a size smaller than 3 cm. Computed tomography helps make a differential diagnosis. The major radiographic difficulty with pulmonary hamartomas is to distinguish them from inflammatory and metastatic lesions. Hamartomas must be differentiated from small primary bronchogenic carcinoma and solitary pulmonary nodules. Specific popcorn-type calcification is almost pathognomonic for pulmonary hamartoma. In our patient, computed tomography of the thorax showed a 3x2-cm mass surrounding the left main bronchus concentrically at the paramediastinal site of the lower lobe of the left lung. The mass, descending aorta, and left inferior pulmonary vein were separated by fat plans, suggesting that the mass was not attached to the major vessels. With these computed tomography findings, the initial diagnosis of the mass included primary lung cancers, bronchial carcinoid tumors, vascular tumors, or benign neoplasms of the lung.
Parenchymal hamartomas are not visible on bronchoscopy. However, indirect tumor findings can be visualized by bronchoscopy. In our patient, computed tomography, bronchoscopy, and transbronchial fineneedle aspiration biopsy were performed preoperatively. Yet, the precise diagnosis was made after histopathological examination.
Surgical treatment is the gold standard in intraparenchymal hamartomas including enucleation, lobectomy or sleeve resection, wedge resection, segmentectomy, and pneumonectomy. Endobronchial hamartomas can be removed successfully through bronchoscopy.[4]
We could easily reach the mass through a left posterolateral thoracotomy in our patient. The mass was firm, fixed, and immobile. Upon detection of malignancy in frozen section analysis, left lower lobectomy and mediastinal lymph node dissection were performed.
Although hamartomas are benign tumors, they may rarely assume malignant characteristics and may be invasive to surrounding tissues.[5] Besides, some other lung pathologies may rarely accompany pulmonary hamartomas such as bronchiectasis, primary lung cancer, tuberculosis, and metastatic tumors of the lung. It has been recommended that patients with hamartoma should be thoroughly evaluated and closely followedup with respect to the risk for associated synchronous malignancies.[6,7]
In addition to hamartomatous lesions in the fibromuscular stroma, squamous cell carcinoma in situ was determined in the epithelial layer of the bronchial structures. The tumor was composed of cartilage, fibromyxoid stroma, and adipose tissue with incorporated bronchiolar epithelium. Areas of severe atypical squamous metaplasia and squamous cell carcinoma in situ were seen in the bronchial epithelium which was surrounded by the basal membrane (Fig. 2b). Hemorrhage and atelectasis sites were noted in the lung parenchyma around the lesion. No pathology apart from intensive anthracosis was observed in lymph node specimens. Based on these findings, the stage of the tumor was rated as TisN0M0.
Tojo et al.[8] reviewed some 50 reports of lung cancer accompanying chondromatous hamartoma and summarized some common features as follows: men past middle age, adenocarcinoma, and lung cancer and chondromatous hamartoma present in the same lobe. In our case, the tumor accompanying hamartoma was squamous cell cancer and it was in situ stage.
In conclusion, hamartomas can be seen together with lung malignancies. However, the question whether the accompanying malignancy is a coincidental occurrence or is associated with malignant growth in the existing hamartoma layer remains uncertain. It should be kept in mind that hamartomas greater than 4-5 cm, firm, and fixed on manual examination during operation should raise suspicion for malignancy. In such cases, perioperative histopathological examination is required to determine the existence of malignancy and the extent of surgical procedure.
1) Kim GY, Han J, Kim DH, Kim J, Lee KS. Giant cystic chondroid
hamartoma. J Korean Med Sci 2005;20:509-11.
2) Sharkey RA, Mulloy EM, ONeill S. Endobronchial hamartoma
presenting as massive haemoptysis. Eur Respir J 1996;
9:2179-80.
3) Kurkcuoglu IC, Demircan S, Kurul IC, Demirag F.
Endobronchial lipomatous hamartoma. Asian Cardiovasc
Thorac Ann 2005;13:372-3.
4) Sahin AA, Aydiner A, Kalyoncu F, Tokgozoglu L, Baris YI.
Endobronchial hamartoma removed by rigid bronchoscope.
Eur Respir J 1989;2:479-80.
5) Poulsen JT, Jacobsen M, Francis D. Probable malignant transformation
of a pulmonary hamartoma. Thorax 1979;34:557-8.
6) Ribet M, Jaillard-Thery S, Nuttens MC. Pulmonary hamartoma
and malignancy. J Thorac Cardiovasc Surg 1994;107:611-4.